Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Clinical trial NCT00880269 · COMPLETED
Trial details
- NCT number
- NCT00880269
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-08-01
- Primary completion
- 2012-02-01
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.